Nordic Life Science 1
TOP STORIES BUSINESS Team Pila Pharma Ulf Hanneli
us, CEO, Diamyd Medical aiming for listing of the company’s shares on one of the unregulated stock exchanges in Sweden, is targeted for Q2-2021. To facilitate the IPO process, Göteborg Corporate Finance has been selected as the capital finance partner. “We will investigate how AI can be used with AI technology company MainlyAI and KTH (the Royal Institute of Technology), will collectively share funding of SEK 13 million from the Swedish Innovation Agency Vinnova for a project that will design, test and build a model for sustainable production using artificial intelligence. The project will be carried out at Diamyd Medical’s Umeå facility, currently under construction. It is hoped, once the solution has been refined, that it can be introduced in companies throughout Sweden. 14 to reduce greenhouse gas emissions and how we can support decision-making and issues regarding production speed, employee well-being, sustainability goals and waste management,” says Ulf Hannelius, CEO, Diamyd. “The goal is to develop tailor-made AI solutions for our production. At the same time, we want to help pave the way for climate-smart technologies and strategies that can be scaled up and applied to production facilities in various industries.” “The cost of developing new drugs increases significantly around phase 2, so listing Pila Pharma at this point in time is a natural step towards successful financing,” says Lars B. Rasmussen, CFO, Pila Pharma. “I am thrilled that we have finally made the decision to list Pila Pharma” says Dorte X. Gram, founder of Pila Pharma. “This will give us a solid platform to continue the development of XEN-D0501 as a new type of diabetes medication.” NORDICLIFESCIENCE.ORG PHOTO ELLINOR COLLING